Purpose of this Study
L19IL2/L19TNF
Who Can Participate?
Eligibility
People can join this study if they have a confirmed case of locally advanced cutaneous squamous cell carcinoma. They must have at least one tumor on or under the skin that can be measured and injected with the study medicine. They must also have cancer that has gotten worse after taking, or cannot tolerate, a type of treatment called immune checkpoint inhibitors. A team of doctors must agree on this. People can also join if their cancer has spread to nearby areas, such as lymph nodes or skin in between the main tumor area.
Age Range
18-100
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study wants to find out how well the combination treatment L19IL2/L19TNF works for people with Cutaneous Squamous Cell Carcinoma. Researchers also want to learn how well patients handle the medicine and whether this treatment helps them live longer.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
Yes
Study Details
Full Title
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment
Principal Investigator
Melodi
Whitley
Protocol Number
PRO00119223
Phase
II
Enrollment Status
Pending Open to Enrollment